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Even though the benefit of superior vena cava resection for lung and mediastinal malignan-
cies remains controversial, the recent international experiences have demonstrated technical
feasibility of such an extended surgery with acceptable postoperative morbidity and mor-
tality. Concerning lung cancer, a multicentric international study over a 40-year period
reports a risk of developing postoperative complications and mortality of 30% and 12%,
respectively, with a 5-year probability of survival of 21%. The same study, analysing the
results of the last 10 years, demonstrated an improvement of the outcome with a 6% of
postoperative mortality, with a 5-year probability of survival of 28%. With regards to medi-
astinal malignancies, completeness of surgical resection is still considered one of the most
important prognostic factors, and extended SVC resection could improve local control and
disease free survival. In conclusion, radical resection of lung cancer and mediastinal malig-
nancies involving SVC, is feasible, and it could lead to permanent cure in carefully selected
patients.
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Introduction
In non-small cell lung cancer (NSCLC) and mediasti-
nal malignancies, superior vena cava (SVC) infiltration
was long considered an absolute contraindication to
surgical resection w1x. The absence of suitable pros-
thetic material for SVC replacement, uncertainties
regarding the effects of SVC clamping, the seemingly
high probability of graft thrombosis and infection after
lung resection, and last but not least, the dismal out-
comes of pilot experiences, strongly discouraged sur-
gical approaches. Nevertheless, work on animals and
* Corresponding author: Tel.: q39-02-5748 9666; fax: q39-02-
57489698.
E-mail: lorenzo.spaggiari@ieo.it
humans in the 1970s and 1980s demonstrated the
technical feasibility of extended surgery for mediasti-
nal and pulmonary malignancies, and long-term sur-
vival was achieved in some instances. To our
knowledge, 11 series reporting more than six patients
undergoing SVC replacement in the context of
NSCLC have been published in the English literature
over the last 15 years w1–12x. Postoperative mortality
ranged from 0% to 22%, with 5-year survival between
21% and 31% (Table 1). In 2004, a multicentric ret-
rospective study was published w10x analysing data
on 109 patients. Major postoperative morbidity and
mortality were 30% and 12%, respectively, and five-
year survival was 21% (28% considering patients
treated over the recent 10 years). These findings
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Table 1. English-language literature review (1990–2005): full papers with more than 6 patients
Ref. Author/year No. of patients Prosthetic graft Mortality 5-year survival
w2x Piccione/1990 6 0 17% NR
w3x Thomas/1994 15 4 7% 24%
w4x Tsuchiya/1994 32 7 22% NR
w5x Dartevelle/1997 14 14 7% 31%
w6x Fukuse/1997 8 3 NR NR
w7x Spaggiari/2000* 25 7 12% 29%
w8x Spaggiari/2000** 11 3 0 NR
w9x Bernard/2001 8 2 NR 25%
w10x Spaggiari/2004 *** 109 26 12% 21%
w11x Shargall/2004 15 9 14% 57% (3 years)
w12x Suzuki/2004 40 11 10% 24%
* Marie Lannelongue Hospital, Paris, experience.
** European Institute of Oncology, Milan, experience.
*** Multicentric study w10x.
showed that SVC surgery is technically feasible, and
also that oncological outcomes can be better than in
patients given chemotherapy and radiation only (five-
year survival 5–17%) w1x.
For mediastinal cancers (thymomas, etc.) in particular,
completeness of resection is a major prognostic fac-
tor. Thus, surgical techniques that allow the accom-
plishment of complete tumour resection, even in the
presence of direct vascular invasion, are urgently
required.
Anatomy
The right and left innominate veins, which receive
venous blood mainly from the upper thorax, arms,
neck and head, are the major vessels returning blood
to the SVC. The SVC begins at the level of the first
right costal cartilage and terminates in the right atrium
at the level of the third intercostal space, and is thus
located in the superior part of the middle mediasti-
num, to the right of the aorta, and anterior to the tra-
chea and right main bronchus. The SVC is about 2 cm
in diameter and 6–8 cm in length; the last 2 cm are
within the pericardial reflection around the right atri-
um. The extrapericardial part of the SVC is surround-
ed by numerous lymph nodes.
A number of other veins drain into the SVC and can
be major contributors to collateral flow and hence are
important in SVC surgical anatomy.
Azygos and hemiazygos veins The azygos is the
thoracic continuation of the right ascending lumbar
vein; it collects blood from the right posterior inter-
costal veins and drains into the posterior SVC, just
above the pericardial reflection. The hemiazygos vein
is the continuation of the left ascending lumbar vein;
it intercepts the lower left posterior intercostal veins,
ascending on the left side of the thoracic spine as far
as the eighth thoracic vertebral body, where it crosses
over the vertebral column to fuse with the azygos
vein.
Paravertebral system This is a low pressure cir-
cumferential venous network that has connections
with the SVC and the inferior vena cava; it consists of
an internal plexus within the spinal canal and an exter-
nal plexus around the vertebral bodies, with anterior
and posterior venous arches.
Lateral thoracic vein This runs vertically, draining
into the axillary vein, which continues as the subcla-
vian vein after passing under the first rib, and as the
brachiocephalic vein after junction with the internal
jugular vein.
Internal mammary (thoracic) vein This runs verti-
cally behind the costal cartilages within the thoracic
wall parallel to the sternum; it drains the anterior inter-
costal veins and superior epigastric vein, and itself
drains into the subclavia.
Other pathways contributing to collateral flow are the
jugular, thyroid, thymic and pericardium phrenic
venous systems.
History
In 1757 William Hunter described a case of SVC syn-
drome caused by a syphilitic aneurysm of the ascend-
ing aorta w13x. In 1837 William Stokes reported the
first case of SVC syndrome caused by a malignancy
w14x. In 1949 McIntire and Sykes reported the first
series of 502 cases with SVC syndrome mainly
caused by benign diseases such as syphilitic aortic
aneurysm and chronic fibrous mediastinitis from
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Photo 1. Patient with thymoma infiltrating SVC and neoplastic
thrombus of right atrial cavity. (A) shows patient on cardiopulmonary
bypass; atriotomy with resection of the SVC and partial resection
of the right atrium. (B): construction of anastomosis between the
right atrium and prosthesis. (C) shows completed anastomosis.
Note the intracavity tumour in (D).
tuberculosis, only a third of the cases were due to
primary thoracic cancers w15x. Prior to 1949, SVC syn-
drome had a mainly infectious etiology, now thoracic
malignancies are the primary cause.
As regards surgery for SVC syndrome, in 1934 Carl-
son working on dogs found that SVC ligation below
the azygos resulted in the death of all animals, while
SVC ligation above the azygos allowed survival, dem-
onstrating that the azygos system is an important col-
lateral pathway w16x. The first successful bypass
operations for SVC obstruction in humans were per-
formed with autologous femoral vein grafts by Klas-
sen in 1951 w17x and Bricker and McAfee in 1952 w18x.
In 1961 Benvenuto and colleagues constructed large
calibre bypass conduits from several segments of
saphenous vein; these were incised longitudinally,
flattened, placed over a stent in a panelled or tiled
manner and sewn together to create the conduit w19x.
In 1961 Schramel and Olinde described the subcu-
taneous tunnelling of a long saphenous vein bypass
conduit to the jugular vein w20x. This technique was
later adopted by Taylor and associates (1974) w21x and
Vincze et al. (1982) w22x in seven patients with SVC
obstruction due to lung cancer. In 1976 Doty and Bak-
er performed the first successful venous bypass with
a spiral saphenous vein graft w23x. This procedure had
been developed two years previously by Chiu and
associates who performed it in a patient with SVC
obstruction secondary to granulomatous mediastinitis
w24x. In 1986 Mitchell and colleagues described two
SVC bypasses using intact saphenous vein in patients
with mediastinal fibrosis w25x.
In 1987 Dartevelle et al. described 13 patients with
mediastinal or lung malignancies and SVC involve-
ment: they were treated by SVC resection and recon-
struction with polytetrafluoroethylene grafts w26x.
Pathology
Lung cancer and thymoma are the malignancies that
most commonly invade the vena cava. NSCLC can
infiltrate the SVC in three ways:
1. Arising in the ventral segment of the right upper
lobe, it may grow to invade the mediastinal pleura,
the phrenic nerve and the anterolateral part of the
SVC. The carina and trachea are often spared.
2. Arising in the central part of the main right bron-
chus, the cancer can directly invade the carina and
SVC posteriorly at its confluence with the azygos.
This type of invasion is often accompanied by R4
lymph node involvement, while the phrenic nerve
is often spared. In such cases the SVC can be
resected en bloc with the carina.
3. The SVC is infiltrated from involved R4 lymph
nodes.
Mediastinic cancers invading the SVC present differ-
ently. Thymomas, for example, usually grow slowly
and asymptomatically and may become large before
being diagnosed. Typically such cancers involve first
the innominate veins and then the SVC. Resection,
therefore, includes the SVC and its major divisions,
and the type of reconstruction required differs from
that employed for invasion from a lung. Because of
the slow growth, one may occasionally observe com-
plete neoplastic thrombosis of the SVC together with
invasion of the atria (Photo 1 A–D) or multi-organ
invasion (aorta, pulmonary arteries, etc.).
These differing habits determine the surgical access
route and the type of vena cava and lung resection
performed.
Patient selection
Oncological selection
A. Lung cancer. The workup of a patient with locally
advanced lung cancer includes bronchoscopy to
determine whether the carina is involved and if nec-
essary plan enlarged bronchial tree resection. Whole
body CT scan and PET scan are essential to deter-
mine whether distant metastases are present which
would contraindicate surgery. If CT scan indicates
operable disease, diagnostic cervical mediastinosco-
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py is then required to exclude R2 node involvement
(which would absolutely contraindicate surgery), and
examine the tracheobronchial angle with a view to
carina removal. The presence of (non bulky) R4 aden-
opathy is not an absolute contraindication to surgery
as these nodes are so close to the tumour. A diag-
nosis of SVC infiltration is always clinical (cT4) as it is
impossible to confirm blood vessel infiltration. After
work-up is complete, the patient undergoes induction
chemotherapy which has the following objectives:
● to extirpate systemic microscopic disease
● to identify rapidly growing disease which would
contraindicate surgery
● to reduce disease extent in the mediastinum and
facilitate resection. On completion of (usually three
cycles of) chemotherapy, the patient is re-staged
with total body CT, PET scan (bronchoscopy in
case of tracheo-bronchial associated invasion).
B. Mediastinal tumours. Work-up in these patients
includes total body CT scan, and PET scan. In cases
of advanced disease it may be useful to perform MRI
of the mediastinum to exclude aortic arch and its
branches invasion. And in such patients diagnostic
cervical mediastinoscopy may not be necessary
because the invasion of the tracheo-bronchial tree is
rare in these tumours, and the infrequent involvement
of mediastinal lymph nodes is not a contraindication
to surgical resection. If right atrial cavity involvement
is suspected, echocardiogram (preferably transeso-
phageal) may be useful. Induction chemotherapy is
generally advisable in bulky mediastinal tumours.
Functional selection The work-up of lung cancer
patients who are candidates for surgery must be com-
plete and include functional evaluation. Spirometry,
perfusion scintigraphy, echocardiography and exer-
cise tolerance test must always be performed to
ensure that cardiorespiratory reserve is adequate.
Surgical procedure
SVC removal requires total clamping which gives rise
to acute intraoperative caval syndrome, whose sever-
ity will vary depending on the extent of pre-existing
caval occlusion and consequent development of col-
lateral circulation. Thus, if SVC involvement has not
obstructed blood flow, complete clamping has major
haemodynamic consequences; whereas if the lumen
is compromised (as typically occurs with mediastinic
tumours), complete clamping has much more modest
repercussions for the pre-existing collateral circles; in
fact it may not be necessary to reconstruct the SVC
following its removal.
Acute intraoperative caval syndrome has several hae-
modynamic aspects: reduction of cardiac in/out put
resulting in an increased venous head pressure and in
reduced systemic arterial pressure. These events lead
to a decrease in pressure gradient in the head result-
ing in marked tissue edema, particularly in the brain.
It is important to take steps to reduce these effects
during surgery. This can be achieved (a) by cardio-
pulmonary bypass, (b) by inserting a temporary shunt
w2x or (c) by means of the cross-clamping technique
w10,27x. Techniques (a) and (b) are only used occa-
sionally in SVC surgery. Cross-clamping is mainly
used, and aims to maintain the vascular brain pres-
sure gradient, so as to avoid edema. Increased
venous pressure is contrasted with vasoactive fluids
and drugs that increase arterial pressure. Rapid SVC
substitution (with complete heparinisation) keeps the
cross-clamping times as short as possible w27x.
Cephalic venous pressure and systemic arterial pres-
sure are monitored continuously during the operation;
as are cardiac filling and haemodynamic changes dur-
ing clamping (preferably by transesophageal ultraso-
nography). A double lumen catheter placed in the
femoral veins allows one to obtain the vascular filling
necessary during clamping.
Several surgical approaches are possible, and may
depend on the personal preferences of the surgeon.
The choice should, however, take into consideration
the type of lung resection being performed, the size
of the lesion, and whether or not the innominate veins
are involved. A mediastinic cancer generally requires
sternotomy or hemi-clamshell, or occasionally a clam-
shell approach. Lung cancer originating in the ventral
segment of the superior lobe, but not involving the
bronchus, can be approached by hemi-clamshell (see
Video 3) or sternotomy; involvement of the bronchus
or carina necessitates (in view of the successive
reconstruction) a lateral or postero-lateral thora-
cotomy.
A partial or total SVC resection is performed depend-
ing on the extent of involvement. When less than 50%
of the circumference is infiltrated, a partial SVC resec-
tion is acceptable. Mechanical sutures (Photo 2), or
continuous sutures after partial clamping may be used
(Photo 3). Sometimes a patch reconstruction is
required: heterologous or synthetic material may be
used (Photo 4).
When more than 50% of the circumference is infil-
trated a prosthesis is required. After a careful explo-
ration of the chest cavity, SVC is dissected from
mediastinal tissues and isolated with vessel loops
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Photo 2. (A–B) Partial resection of SVC by stapler after complete
control of the vessel, but without clamping, for infiltration of azygos-
caval confluence; (C) shows reduction in the final calibre of SVC.
Photo 3. A similar case to that illustrated in Photo 2. Resection
performed after partial SVC clamping. SVC reconstruction by a run-
ning polypropylene 5/0 suture.
Photo 4. After partial SVC resection (A) a patch of autologous per-
icardium has been used to repair the defect (B). In this case the
SVC clamping was complete.
Video 1. (Patient A). This patient had NSCLC originating in the right
main bronchus and infiltrating the carina. Mediastinoscopy was per-
formed to exclude R2 nodal involvement. Induction chemotherapy
was given. Given the need to remove the carina and the SVC,
access was via lateral thoracotomy, sparing the muscle of the 5th
intercostal space and section of the 4th costal cartilage. The oper-
ation proceeded initially with dissection of the SVC to achieve con-
trol of the vessel at its confluence with the innominate veins.
(Videos 1–4), and then clamped using the cross-
clamping technique previously described (Videos 5
and 6). For a long time, the prostheses used were
synthetic, typically PTFE graft (Photos 5–10) (Video 7).
Autologous materials have been also used (saphe-
nous vein, pericardium etc.); recently we adopted a
heterologous (bovine) pericardium graft made tubular
during operation (Photos 11–13) (Videos 8–11).
Generally the prosthesis joins two ends of the SVC
(Photos 5 and 6) (Videos 10 and 11). Sometimes the
anastomosis may be between the left innominate vein
and the SVC origin (Photo 9), removing the right
venous trunk without reconstructing. Alternatively the
anastomosis may be between the right innominate
vein and the SVC, following total removal of the left
innominate vein (Photos 13 and 14). Sometimes it is
necessary to reconstruct the resected innominate vein
(Photo 10B) or completely remove the left innominate
vein and partially resect the SVC (Photo 15). Use of
heparin (0.5 mg/kg) prevents thrombosis during pros-
thesis placement.
After SVC replacement, the tracheo-bronchial involve-
ment (if associated), is removed and the airway recon-
structed (Video 12).
Before discharge, the patency of the graft is studied
by using both thoracic CT scan and phlebography;
the follow-up of the graft, and of the oncological dis-
ease performed by periodical total body CT scan (Vid-
eo 13).
Results
Two questions immediately arise with regard to SVC
surgery: is it feasible? (is it reproducible with accept-
able morbidity and mortality?); and is it oncologically
worthwhile? (Are results better than combination che-
motherapy and radiotherapy?).
The technical feasibility of the operation was
demonstrated in the 1970s and 1980s, supported by
studies published in the 1990s. Postoperative com-
plications and perioperative deaths (up to 30 days)
were highly dependent on the surgeon’s experience,
type of SVC surgery performed (partial vs. complete
SVC resection) and type of lung resection (lobectomy
vs. tracheal sleeve pneumonectomy).
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Video 2. (Patient A). The opening of the pericardium allows to con-
trol the SVC just before its entry into the right atrium. Dissection of
the lymph nodes in Barety’s space at this point favours control of
the vessel. The right pulmonary artery is isolated within the Teile’s
sinus.
Video 3. (Patient B). This patient had lung cancer originating in the
ventral part of the right superior lobe, without lymph node involve-
ment by mediastinoscopy, and without bronchial tree involvement.
A hemi-clamshell was used for access. The SVC was isolated after
complete mediastinic dissection (mediastinic adipose and thymus).
Video 4. (Patient B). In this case, the surgical approach chosen
(hemi-clamshell) facilitated control of the innominate veins and sep-
arate control of the SVC, after opening the pericardium.
Video 5. (Patient B). Here the vena cava was cross-clamped as
described previously without the use of extracorporeal circulation
or a shunt. Heparin (0.5 mg/kg) was administered prior to clamping.
Video 6. (Patient C). Same technique (cross clamping technique) as
described in Video 5.
Photo 5. Complete SVC substitution. Hemi-clamshell approach;
right superior lobectomy, reinforced PTFE prosthesis (size 14) for
SVC–SVC anastomosis (A). (B) shows that the cancer has infiltrated
the entire thickness of the vessel.
Photo 6. Complete SVC substitution. Approach: lateral thoracoto-
my; lung resection: tracheal sleeve pneumonectomy; ringed PTFE
(size 14) prosthesis serves to achieve SVC–SVC anastomosis.
Photo 7. (A–B). Complete SVC substitution. Approach: lateral tho-
racotomy; lung resection: tracheal sleeve lobectomy with neocarina
(B) SVC–SVC anastomosis with PTFE prosthesis (size 14).
Table 1 summarizes postoperative mortality in recent
published series. The recently-published multicentric
study w10x on 109 patients operated on over a 40-year
period, reported intraoperative mortality at 0%. Post-
operative morbidity at 33% and postoperative mor-
tality of 12%. Respiratory complications (60%) were
responsible for 92% of postoperative deaths; 4.5%
(5/109) of patients developed early SVC thrombosis:
three of the 28 (11%) who received complete resec-
tion with prosthetic substitution, and two of the 80
(2.5%) who received partial SVC resection. Prosthesis
infection occurred in 7% (2/28).
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Photo 8. Complete SVC substitution. Both innominate veins resect-
ed for mediastinic tumour; approach: sternotomy; no lung resection;
ringed PTFE (size 12) prosthesis for anastomosis between left
innominate vein and SVC.
Photo 10. Left innominate vein substitution and partial SVC resec-
tion for mediastinic tumour. Approach: sternotomy; lung resection:
left superior lobectomy with complete antero–superiormediastinec-
tomy and pericardiectomy (B). Left innominate vein reconstructed
with autologous pericardium (A).
Video 7. (Patient C). Revascularisation of the SVC by ringed PTFE
prosthesis.
Photo 9. Complete SVC substitution. Approach: lateral thoracoto-
my; lung resection: superior right double sleeve lobectomy; ringed
PTFE (n. 10) prosthesis for pulmonary artery; and ringed PTFE (size
12) prosthesis for SVC–SVC anastomosis.
Photo 11. Complete SVC substitution for NSCLC. Approach: lateral
thoracotomy; lung resection: tracheal sleeve. SVC reconstructed
with heterologous pericardial graft, SVC-SVC anastomosis.
Mean intensive stay period was three days and mean
hospitalisation was 16 days. With regard to long-term
outcomes, median survival was 11 months and 5-year
survival probability was 21%. Because the analysis
covered a very long recruitment period, in which sur-
geons’ experiences were variable and over which
technology changed greatly, a separate analysis on
patients operated on over the last 10 years was also
presented. In this series postoperative mortality was
6% with 5-year survival of 28%.
Multivariate analysis identified performance of pneu-
monectomy as negatively influencing prognosis and
type of SVC revascularisation as also independently
influencing prognosis.
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Photo 12. Similar case as Photo 11. Complete SVC substitution for
NSCLC. Approach: lateral thoracotomy; lung resection: tracheal
sleeve. SVC reconstructed with heterologous pericardial prosthesis,
SVC–SVC anastomosis. Note the reconstruction of the pericardial
defect with the same pericardial patch used for SVC prosthesis.
Photo 13. Complete SVC substitution with right and left innominate
vein resection for invasive thymoma after chemo-radiation therapy.
Approach: sternotomy. Lung resection: right upper lobectomy. SVC
reconstruction with custom-made heterologous pericardial tube,
between right innominate vein and SVC.
Video 8. (Patient A). The SVC was substituted with a prosthesis of
bovine pericardium formed into a tube. The required 2 cm diameter
was obtained with tutors and continuous polypropylene suturing
5/0. Prosthesis length was close to that of the resected SVC.
Video 9. (Patient B). Same technique as Video 8.
Video 10. (Patient B). The proximal anastomosis of the bovine cus-
tom-made prosthesis with the innominate veins confluence was
constructed first using continuous polypropylene 5/0 sutures, fol-
lowed by the anastomosis with SVC. The lung resection was a right
superior lobectomy.
Video 11. (Patient A). The proximal anastomosis of the bovine cus-
tom-made prosthesis with the innominate veins confluence was
constructed first using continuous polypropylene 5/0 sutures, fol-
lowed by the anastomosis with SVC. The lung resection was a tra-
cheal sleeve pneumonectomy.
Our recent experience (personal communication, STS
Chicago, 2006) consists of 70 patients who under-
went SVC resection at the European Institute of
Oncology from 1998 to 2004; 52 were operated on for
NSCLS and 18 for mediastinic tumour. Lung cancer
patients received induction chemotherapy in 77% of
cases. Major postoperative morbidity and mortality
were 23% and 7.7%, respectively (50% and 5.6% in
mediastinal tumours). In the lung cancer group, medi-
an survival was 16.2 months (95% CI 12.6–36.7) with
5-year survival probability of 31%. Median survival for
mediastinal tumours was 49 months.
Conclusions
SVC infiltration implies at least locally advanced lung
cancer for which combined chemotherapy and radio-
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Photo 14. Complete SVC substitution with right and left innominate
veins resection for NSCLC. Approach: transmanubrial and lateral
thoracotomy. Lung resection: right superior lobectomy. SVC recon-
structed with PTFE (size 12) prosthesis and anastomosis between
right innominate vein and SVC.
Photo 15. Germ cell cancer of mediastinum. Approach: clamshell
and median sternotomy; partial resection of SVC and left innomi-
nate vein; no reconstruction.
Video 12. (Patient A). In this case of SVC resection, tracheal sleeve
pneumonectomy was necessary. After carinal resection, ventilation
was achieved by intubation of the left main bronchus. The trachea
was anastomosed with continuous double polypropylene sutures
3/0. The bronchial anastomosis was separated from the caval pros-
thesis using a flap of intercostal muscle and a flap of vascularised
mediastinic fat. The surgical specimen shows the carina en bloc
with the right lung and the SVC.
Video 13. (Patient A). Postoperative CT of the thorax, phlebography
and 3D reconstruction of the airway.
therapy gives five year survival in the range 5%–17%.
SVC resection is feasible: in that postoperative com-
plications and mortality are acceptable using modern
patient selection criteria. Patients with extensive nodal
involvement (R2 nodes involved) or SVC infiltration
from bulky N2, should not be candidates for SVC
resection as oncological radicality will not be possible.
Induction chemotherapy is advisable to identify
patients with aggressive disease, and reduce the
extent of resection.
Five year survival probability in all published studies
is better than that obtained by chemotherapy/radio-
therapy and is in the range 25%–31%. The use of
heterological prosthesis material, such as animal per-
icardium, promises to reduce the rate of infective and
thrombotic postoperative complications.
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